Summary
132.87 0.19(0.14%)05/17/2024
Moderna Inc (MRNA)
Moderna Inc (MRNA)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -0.81 | 9.73 | 15.29 | 21.87 | 64.42 | -8.08 | 393.32 | 551.13 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 121.11 | |
| Open | 122.86 | |
| High | 123.49 | |
| Low | 118.68 | |
| Volume | 2,434,992 | |
| Change | -0.99 | |
| Change % | -0.81 | |
| Avg Volume (20 Days) | 3,023,371 | |
| Volume/Avg Volume (20 Days) Ratio | 0.81 | |
| 52 Week Range | 62.65 - 142.79 | |
| Price vs 52 Week High | -15.18% | |
| Price vs 52 Week Low | 93.31% | |
| Range | -1.42 | |
| Gap Up/Down | -2.29 | |
Fundamentals | ||
| Market Capitalization (Mln) | 50,933 | |
| EBIDTA | 7,772,106,752 | |
| PE Ratio | 16.6044 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 301.20 | |
| Book Value | 24.9980 | |
| Earnings Per Share | 16.6920 | |
| EPS Estimate Current Quarter | 9.0500 | |
| EPS Estimate Next Quarter | 10.9700 | |
| EPS Estimate Current Year | 25.8900 | |
| EPS Estimate Next Year | 26.5800 | |
| Diluted EPS (TTM) | 16.6920 | |
| Revenues | ||
| Profit Marging | 0.5968 | |
| Operating Marging (TTM) | 0.6433 | |
| Return on asset (TTM) | 0.3720 | |
| Return on equity (TTM) | 1.0961 | |
| Revenue TTM | 11,831,395,328 | |
| Revenue per share TTM | 29.5170 | |
| Quarterly Revenue Growth (YOY) | 30.6500 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | -574,877,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 16.6044 | |
| Forward PE | 10.6270 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 10.2948 | |
| Revenue Enterprise Value | 8.1057 | |
| EBITDA Enterprise Value | 12.3257 | |
| Shares | ||
| Shares Outstanding | 405,449,984 | |
| Shares Float | 367,385,925 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 9.51 | |
| Institutions (%) | 61.15 | |
05/17 12:00 EST - reuters.com
Moderna wins case in patent dispute with Pfizer, BioNTech over COVID shot, FT reports
Moderna has won a case at the European Patent Office in its dispute with Pfizer and BioNTech over its COVID-19 vaccine, the Financial Times reported on Friday.
Moderna wins case in patent dispute with Pfizer, BioNTech over COVID shot, FT reports
Moderna has won a case at the European Patent Office in its dispute with Pfizer and BioNTech over its COVID-19 vaccine, the Financial Times reported on Friday.
05/17 05:40 EST - fool.com
Could Novavax Become the Next Moderna?
Moderna's sales soared into the billions as it conquered the coronavirus vaccine market -- and today the company promises to deliver many new products in the near term. Novavax struggled in recent times, but it's alliance with a vaccine market giant could turn things around.
Could Novavax Become the Next Moderna?
Moderna's sales soared into the billions as it conquered the coronavirus vaccine market -- and today the company promises to deliver many new products in the near term. Novavax struggled in recent times, but it's alliance with a vaccine market giant could turn things around.
05/14 06:35 EST - fool.com
Is This a Setback for Moderna?
Moderna's waiting for the FDA to give it a nod for its next potential blockbuster -- an RSV vaccine. But the FDA is taking longer than planned to review the vaccine candidate.
Is This a Setback for Moderna?
Moderna's waiting for the FDA to give it a nod for its next potential blockbuster -- an RSV vaccine. But the FDA is taking longer than planned to review the vaccine candidate.
05/13 12:26 EST - zacks.com
Moderna (MRNA) Falls as FDA Extends Review Time for RSV Vaccine
Moderna's (MRNA) RSV vaccine, mRNA-1345's review timeline gets delayed. A decision is now expected by the end of May.
Moderna (MRNA) Falls as FDA Extends Review Time for RSV Vaccine
Moderna's (MRNA) RSV vaccine, mRNA-1345's review timeline gets delayed. A decision is now expected by the end of May.
05/13 10:02 EST - zacks.com
Investors Heavily Search Moderna, Inc. (MRNA): Here is What You Need to Know
Moderna (MRNA) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Investors Heavily Search Moderna, Inc. (MRNA): Here is What You Need to Know
Moderna (MRNA) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
05/13 08:45 EST - fool.com
Bull Market and Beyond: 2 Stocks Just Waiting to Soar
Moderna has a deep pipeline that should help it land brand-new approvals regularly. DexCom has a massive opportunity in the vast continuous glucose monitoring market.
Bull Market and Beyond: 2 Stocks Just Waiting to Soar
Moderna has a deep pipeline that should help it land brand-new approvals regularly. DexCom has a massive opportunity in the vast continuous glucose monitoring market.
05/13 07:00 EST - accesswire.com
Moderna to Present at Upcoming Conferences in May/June 2024
CAMBRIDGE, MA / ACCESSWIRE / May 13, 2024 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conferences: Bernstein's 40th Annual Strategic Decisions Conference (SDC), on Friday, May 31st at 10:00am ET Jefferies Healthcare Conference, on Thursday, June 6th at 10:00am ET Goldman Sachs 45th Annual Global Healthcare Conference, on Monday, June 10th at 1:20pm ET A live webcast of each of these presentations will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com. A replay of each webcast will be archived on Moderna's website for at least 30 days following the presentation.
Moderna to Present at Upcoming Conferences in May/June 2024
CAMBRIDGE, MA / ACCESSWIRE / May 13, 2024 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conferences: Bernstein's 40th Annual Strategic Decisions Conference (SDC), on Friday, May 31st at 10:00am ET Jefferies Healthcare Conference, on Thursday, June 6th at 10:00am ET Goldman Sachs 45th Annual Global Healthcare Conference, on Monday, June 10th at 1:20pm ET A live webcast of each of these presentations will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com. A replay of each webcast will be archived on Moderna's website for at least 30 days following the presentation.
05/12 09:25 EST - fool.com
Moderna and OpenAI Are Teaming Up, but Does That Make the Stock a Buy?
Moderna is using OpenAI's ChatGPT and other tools extensively. In particular, OpenAI's solution is helping with some much-dreaded work.
Moderna and OpenAI Are Teaming Up, but Does That Make the Stock a Buy?
Moderna is using OpenAI's ChatGPT and other tools extensively. In particular, OpenAI's solution is helping with some much-dreaded work.
05/10 12:45 EST - investopedia.com
Moderna Stock Slips as FDA Delays RSV Vaccine Approval
Moderna (MRNA) shares lost ground in intraday trading Friday as the biotech's effort to move beyond just a COVID-19 vaccine was stalled somewhat by U.S. regulators looking at its new shot to treat respiratory syncytial virus (RSV).
Moderna Stock Slips as FDA Delays RSV Vaccine Approval
Moderna (MRNA) shares lost ground in intraday trading Friday as the biotech's effort to move beyond just a COVID-19 vaccine was stalled somewhat by U.S. regulators looking at its new shot to treat respiratory syncytial virus (RSV).
05/10 07:45 EST - marketwatch.com
Moderna says FDA will not complete review of RSV vaccine by May 12 deadline
Moderna Inc.'s stock fell 1.8% early Friday, after the company said the Food and Drug Administration will not complete its review of the company's respiratory syncytial virus, or RSV, vaccine by the original deadline of May 12.
Moderna says FDA will not complete review of RSV vaccine by May 12 deadline
Moderna Inc.'s stock fell 1.8% early Friday, after the company said the Food and Drug Administration will not complete its review of the company's respiratory syncytial virus, or RSV, vaccine by the original deadline of May 12.
05/10 07:24 EST - marketbeat.com
Will the Biotech Sector Shift From Lagger to Leader?
The biotech sector and its popular ETF, the iShares Biotechnology ETF NASDAQ: IBB, have lagged the overall market during the year, with its shares slightly red. However, in recent weeks, the sector has enjoyed a significant rally after bouncing off its uptrend support and now consolidating near several major Simple Moving Averages (SMA).
Will the Biotech Sector Shift From Lagger to Leader?
The biotech sector and its popular ETF, the iShares Biotechnology ETF NASDAQ: IBB, have lagged the overall market during the year, with its shares slightly red. However, in recent weeks, the sector has enjoyed a significant rally after bouncing off its uptrend support and now consolidating near several major Simple Moving Averages (SMA).
05/10 07:07 EST - reuters.com
US FDA pushes decision on Moderna's RSV vaccine to end of this month
The U.S. Food and Drug Administration has pushed back its decision on Moderna's respiratory syncytial virus (RSV) vaccine by more than two weeks to the end of this month due to some "administrative constraints", the company said on Friday.
US FDA pushes decision on Moderna's RSV vaccine to end of this month
The U.S. Food and Drug Administration has pushed back its decision on Moderna's respiratory syncytial virus (RSV) vaccine by more than two weeks to the end of this month due to some "administrative constraints", the company said on Friday.
05/10 07:00 EST - cnbc.com
Moderna says FDA delayed RSV vaccine approval to end of May
The FDA has not informed Moderna of any issues related to the vaccine's safety, efficacy or quality that would prevent its approval, the biotech company said.
Moderna says FDA delayed RSV vaccine approval to end of May
The FDA has not informed Moderna of any issues related to the vaccine's safety, efficacy or quality that would prevent its approval, the biotech company said.
05/10 07:00 EST - accesswire.com
Moderna Announces Update on Investigational RSV Vaccine
U.S. FDA has informed Moderna that due to administrative constraints, the agency will not complete its review of mRNA-1345 by the PDUFA date of May 12, 2024 Agency has indicated it expects to complete the review by end of May CAMBRIDGE, MA / ACCESSWIRE / May 10, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced it has been notified by the U.S. Food and Drug Administration (FDA) that due to administrative constraints, the agency does not expect to complete its review of the Biologics License Application (BLA) for mRNA-1345, Moderna's investigational respiratory syncytial virus (RSV) vaccine, by the previously communicated Prescription Drug User Fee Act (PDUFA) date of May 12, 2024. The FDA has informed Moderna that it is working to conclude the review by the end of May 2024.
Moderna Announces Update on Investigational RSV Vaccine
U.S. FDA has informed Moderna that due to administrative constraints, the agency will not complete its review of mRNA-1345 by the PDUFA date of May 12, 2024 Agency has indicated it expects to complete the review by end of May CAMBRIDGE, MA / ACCESSWIRE / May 10, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced it has been notified by the U.S. Food and Drug Administration (FDA) that due to administrative constraints, the agency does not expect to complete its review of the Biologics License Application (BLA) for mRNA-1345, Moderna's investigational respiratory syncytial virus (RSV) vaccine, by the previously communicated Prescription Drug User Fee Act (PDUFA) date of May 12, 2024. The FDA has informed Moderna that it is working to conclude the review by the end of May 2024.
05/09 11:35 EST - youtube.com
Moderna's Promise of mRNA Undercut by New RSV Vaccine
Moderna's second vaccine, meant to prevent a common respiratory virus, is calling into question the premise on which the company has staked its entire business. Gerry Smith reports on Bloomberg Television.
Moderna's Promise of mRNA Undercut by New RSV Vaccine
Moderna's second vaccine, meant to prevent a common respiratory virus, is calling into question the premise on which the company has staked its entire business. Gerry Smith reports on Bloomberg Television.
05/09 09:05 EST - fool.com
If You'd Invested $1,000 in Moderna Stock 5 Years Ago, Here's How Much You'd Have Today
Prior to the COVID pandemic, the biopharma outfit wasn't a particularly well-known name. Being one of the few pharma companies that could quickly come up with a vaccine, however, catapulted its stock.
If You'd Invested $1,000 in Moderna Stock 5 Years Ago, Here's How Much You'd Have Today
Prior to the COVID pandemic, the biopharma outfit wasn't a particularly well-known name. Being one of the few pharma companies that could quickly come up with a vaccine, however, catapulted its stock.
05/08 10:30 EST - investorplace.com
Just Say No to Drugs: 3 Pharma Stocks to Avoid
From its stellar performance in 2021 to deflating in 2022, the biotech sector continued its stagnation into 2023, highlighting some pharma stocks to avoid. Year-to-date, the S&P Biotechnology Select Industry Index has dropped by 4%.
Just Say No to Drugs: 3 Pharma Stocks to Avoid
From its stellar performance in 2021 to deflating in 2022, the biotech sector continued its stagnation into 2023, highlighting some pharma stocks to avoid. Year-to-date, the S&P Biotechnology Select Industry Index has dropped by 4%.
05/06 11:53 EST - youtube.com
MRNA, GILD: What to Watch in Biotech Stocks
Fiscal discipline is important going forward, notes Hartaj Singh on Moderna (MRNA). He discusses biotech stocks Moderna and Gilead Sciences (GILD).
MRNA, GILD: What to Watch in Biotech Stocks
Fiscal discipline is important going forward, notes Hartaj Singh on Moderna (MRNA). He discusses biotech stocks Moderna and Gilead Sciences (GILD).
05/05 03:00 EST - barrons.com
Largest U.S. Pension Sold Verizon, Disney, and Peloton Stock. It Bought Moderna.
Calpers slashed investments in Verizon, Disney, and Peloton stock, and doubled down on Moderna shares in the first quarter.
Largest U.S. Pension Sold Verizon, Disney, and Peloton Stock. It Bought Moderna.
Calpers slashed investments in Verizon, Disney, and Peloton stock, and doubled down on Moderna shares in the first quarter.